Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer collaborates with biotech firm to detect global disease outbreaks
Lifebit's REAL platform will monitor and interpret scientific publications and other open sources to identify infectious disease outbreaks.

Project will combine real-world evidence with AI to track transboundary infections.

Boehringer Ingelheim has announced a multi-year partnership with biotech firm Lifebit to detect and report global disease outbreaks. 

Through the partnership, scientists will work collaboratively to combine real-world evidence and the latest AI algorithms to identify diseases, particularly those that cross borders, and respond accordingly. 

Lifebit's REAL platform analyses data harvested from millions of tweets, news articles and scientific publications to notify users of relevant disease outbreaks, such as COVID-19. 

As well as speeding up the detection of the latest outbreaks, researchers hope the insights will enable Boehringer’s research and development efforts to be prioritised accordingly.

“External innovation is becoming an increasingly important aspect of our R&D playbook. Therefore, we are strategically partnering with Lifebit to leverage AI to monitor and interpret scientific and other sources in real-time, enabling us to track data related to animal diseases,” commented Dr Eric Haaksma, head of animal health global innovation at Boehringer Ingelheim.

“This, in turn, will accelerate the detection process as the vast amounts of scientific relevant information being produced at many levels cannot be feasibly collected and analysed manually.”

Lifebit CEO Dr Maria Chatzou-Dunford added: “At Lifebit, we thrive at connecting both, locked-up sensitive biomedical data from around the world and AI-driven automated RWE data insights – so that companies at the cutting edge of science, like Boehringer Ingelheim, can make faster and smarter decisions – delivering insights that change lives.”

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.